Trial Profile
Randomized Double Blind Placebo Controlled Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Botulinum toxin B (Primary)
- Indications Hidradenitis suppurativa
- Focus Proof of concept; Therapeutic Use
- 06 Aug 2020 Primary endpoint (Patient reported improvement after invention with Botulinum toxin B) has been met according to the results published in the American Journal of Clinical Dermatology
- 06 Aug 2020 Results published in the American Journal of Clinical Dermatology
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.